Mayne Pharma share price on watch ahead of AGM update

The Mayne Pharma Ltd (ASX: MYX) share price is on watch on the ASX after a trading update from the company's annual general meeting (AGM).

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Mayne Pharma Group Ltd (ASX: MYX) share price is on watch this morning ahead of the company's annual general meeting (AGM).

What could move the Mayne Pharma share price?

Mayne Pharma provided an update on its FY20 trading performance so far.

The US generic pharmaceuticals market "continues to have challenging dynamics", according to CEO Scott Richards.

Aggressive contracting behaviour from three major buying groups that control 90% of retail generic drug purchasing are behind the market headwinds.

Mr. Richards said price deflation and volume has been evident in the market since it peaked in 2016.

The Mayne Pharma share price will be one to watch, given the softer conditions forecast for the short to mid-term as it looks to move away from the generics sector.

The company's focus is on rebalancing its portfolio to better protect and grow sustainable revenue and profit streams.

What about Mayne Pharma's revenues?

Group revenue for the four months in FY20 is down 16% from last year to $153 million. Mayne Pharma reported lower gross margin due to a changed sales mix and inventory obsolescence from generics. 

Generics Production Division revenue growth was down 26% on the prior corresponding period (pcp) but flat on the first four months of 2019.

The realignment of the business is expected to provide a boost with Mayne Pharma's women's health portfolio growing 50% on pcp.

The company's Metrics Contract Services grew revenue by 16% on pcp to $26 million.

Mayne Pharma is bullish on its new E4/DRSP oral contraceptive product after announcing a deal with Mithra Pharmaceuticals in the United States.

Investors will be hoping to see a boost for the Mayne Pharma share price in 2021 when sales of the new product are expected to begin.

What about Mayne Pharma's outlook?

Volatility in results has been a factor in recent years due to FDA approvals, competitor launches and withdrawals of key products.

Mayne Pharma therefore declined to provide earnings guidance for FY20 for those reasons.

Mr. Richards noted the company's strong generics pipeline and the focus on growing its women's health portfolio into 2020.

The Mayne Pharma share price will be worth watching this morning given the headwinds cited by management today.

Motley Fool contributor Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »